Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:32 pm Sale | 2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | Nantahala Capital Management, LLC | 2,340,333 4.380% | -583,688 (-19.96%) | Filing History |
| 2025-02-12 09:32 am Purchase | 2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | Adage Capital Management L.P. | 3,650,000 6.840% | 3,650,000 (New Position) | Filing History |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 4,080,420 7.600% | 1,670,131 (+69.29%) | Filing History |
| 2024-11-14 4:53 pm Purchase | 2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA | Nantahala Capital Management, LLC | 2,924,021 5.557% | 470,616 (+19.18%) | Filing History |
| 2024-11-14 1:00 pm Purchase | 2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA | Woodline Partners LP | 4,048,653 7.700% | 4,048,653 (New Position) | Filing History |
| 2024-11-12 5:59 pm Unchanged | 2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA | The Vanguard Group | 2,756,061 5.230% | 0 (Unchanged) | Filing History |
| 2024-11-04 2:15 pm Purchase | 2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA | The Vanguard Group | 2,756,061 5.230% | 2,756,061 (New Position) | Filing History |
| 2024-02-14 4:51 pm Purchase | 2023-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | Nantahala Capital Management, LLC | 2,453,405 6.200% | 2,453,405 (New Position) | Filing History |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 2,410,289 5.800% | 1,557,440 (+182.62%) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 852,849 2.500% | -1,382,693 (-61.85%) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 2,235,542 6.300% | 2,235,542 (New Position) | Filing History |
| 2022-01-12 4:03 pm Sale | 2022-01-04 | 13G | Zevra Therapeutics, Inc. ZVRA | Braun Samuel J | 3,021,660 8.600% | -355,900 (-10.54%) | Filing History |
| 2022-01-11 10:30 am Sale | 2021-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | Empery Asset Management LP | 801,670 2.220% | -428,330 (-34.82%) | Filing History |
| 2021-12-01 08:25 am Purchase | 2021-11-30 | 13D | Zevra Therapeutics, Inc. ZVRA | Braun Samuel J | 3,377,560 9.600% | 222,560 (+7.05%) | Filing History |
| 2021-05-17 4:43 pm Purchase | 2021-05-10 | 13G | Zevra Therapeutics, Inc. ZVRA | Braun Samuel J | 3,155,000 11.100% | 1,098,500 (+53.42%) | Filing History |
| 2021-04-19 5:12 pm Purchase | 2021-04-09 | 13G | Zevra Therapeutics, Inc. ZVRA | Braun Samuel J | 2,056,500 7.200% | 2,056,500 (New Position) | Filing History |
| 2021-03-09 10:38 am Purchase | 2020-12-31 | 13G | KemPharm, Inc. KMPH | Mangless Daniel John | 700,000 3.700% | 575,000 (+460.00%) | Filing History |
| 2021-02-16 07:01 am Purchase | 2020-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | Delaware Street Capital Master Fund L.P. | 159,364 3.400% | 159,364 (New Position) | Filing History |
| 2021-02-12 2:23 pm Sale | 2021-02-08 | 13G | Zevra Therapeutics, Inc. ZVRA | Auctus Fund LLC | 450,000 2.380% | -550,000 (-55.00%) | Filing History |
| 2021-02-11 8:14 pm Purchase | 2020-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | Mickle Travis C | 227,545 4.900% | 227,545 (New Position) | Filing History |